Pharmacological Adjuvants to Limit Erythropoietin Stimulating Agents Exposure  

作　　者：Iqbal Masood Geoffrey Teehan 

机构地区：[1]Department of Nephrology, Lankenau Medical Center and Lankenau Institute for Medical Research, Wynnewood, USA

出　　处：《Open Journal of Nephrology》2012年第4期86-96,共11页肾脏病（英文）

摘　　要：Anemia in chronic kidney disease (CKD) is common, causing morbidity and mortality, and is primarily due to reduced erythropoietin (EPO) release and, to a lesser degree, shortened red cell survival. Erythropoietin Stimulating Agents like epoetin Alfa and darbepoetin alpha are used commonly to treat this form of anemia. Recent evidence suggests increased morbidity and mortality associated with higher hemoglobin in the setting of these agents use. Whether these complications are due to higher dose of erythropoietin or its resistance (i.e. inflammation), or achieving a higher hemoglobin remains unclear. Tightening restrictions on these agents has led to increase interest in the use of non-ESA adjuvants to improve erythropoiesis. This review will highlight the most promising of these agents.Anemia in chronic kidney disease (CKD) is common, causing morbidity and mortality, and is primarily due to reduced erythropoietin (EPO) release and, to a lesser degree, shortened red cell survival. Erythropoietin Stimulating Agents like epoetin Alfa and darbepoetin alpha are used commonly to treat this form of anemia. Recent evidence suggests increased morbidity and mortality associated with higher hemoglobin in the setting of these agents use. Whether these complications are due to higher dose of erythropoietin or its resistance (i.e. inflammation), or achieving a higher hemoglobin remains unclear. Tightening restrictions on these agents has led to increase interest in the use of non-ESA adjuvants to improve erythropoiesis. This review will highlight the most promising of these agents.

关 键 词：Anemia Chronic Kidney DISEASE (CKD) End Stage Renal DISEASE (ESRD) ERYTHROPOIESIS Stimulating AGENTS (ESA) EPOETIN Alfa (EPO) 

分 类 号：R73[医药卫生—肿瘤]